蛋白C活性检测不同测量程序间样本结果可比性与参考物质互换性研究
研究评估三种蛋白C活性测量程序(Sysmex CS-5100、IL ACL TOP 700、STA-R Evolution)对92份临床样本结果的可比性,并基于生物学变异和外质评标准设定可比性允许限与互换性判定标准。结果显示相应校准模式下临床样本符合率为94.6-100%,WHO IS 02/342、HemosIL校准血浆及候选参考物质PC20201和PC20202在三对测量程序间均可互换。
要点
- 基于生物学变异与外质评标准设定可比性允许限和互换性判定标准可行。
- 三种测量程序在相应校准模式下临床样本符合率为94.6-100%。
- WHO IS 02/342等六种参考物质中四种在三对测量程序间可互换。
核心结论
- 基于生物学变异数据和外质评标准设定可比性允许限与互换性判定标准是可行的。
- WHO IS 02/342、HemosIL校准血浆及候选参考物质PC20201和PC20202在三对测量程序间可互换。
研究设计与样本
- 依据CLSI EP9及既往研究,用92份临床样本评估三种蛋白C活性测量程序间的可比性。
- 采用国际临床化学与实验室医学联合会推荐的差值偏差法评估六种参考物质的互换性。
主要发现
- 在相应校准模式下,临床样本结果符合率为94.6-100%。
- WHO IS、HemosIL校准血浆、PC20201和PC20202在三对测量程序间均可互换。
关键数值与推荐
- 可比性允许限与互换性判定标准基于可靠生物学变异数据计算的总误差及外质评标准设定。
- 临床样本符合率范围为94.6-100%(对应相应校准模式)。
临床怎么用
- 临床实验室在选择蛋白C活性测量程序时应验证样本结果可比性并关注参考物质互换性。
- 采用相应校准模式可使临床样本结果符合率处于94.6-100%范围。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Several types of measurement procedures (MPs) for protein C activity assays are currently available. Clinical sample (CS) results among different MPs should be comparable. The commutability of reference materials (RMs) is an essential requirement to achieve comparability of CS results. MATERIALS AND METHODS: Considering the total error calculated using reliable biological variation (BV) data and external quality assessment (EQA) criteria, we chose the allowable limits of comparability and criterion of commutability. According to Clinical and Laboratory Standardization Institute EP9 and our previous studies, 92 CSs were used to evaluate the comparability among the three MPs (Sysmex CS-5100, IL ACL TOP 700, and STA-R Evolution). The difference in bias method recommended by International Federation of Clinical Chemistry and Laboratory Medicine was used to assess the commutability of six RMs, including World Health Organization (WHO) IS 02/342. RESULTS: The compliance rates of CSs were 94.6-100% with the corresponding calibration mode. WHO IS, HemosIL calibration plasma, and candidate RMs, PC20201 and PC20202, were commutable between each pair of the three MPs. CONCLUSION: It is feasible to set the allowable limits of comparability and the criterion of commutability based on the BV and EQA criteria.
引用
- Hu G, Sun Z, Yu Z, et al. Comparability of sample results and commutability of reference materials among different measurement procedures for protein C activity assays. Clin Chim Acta. 2021. PMID: 34785204. doi:10.1016/j.cca.2021.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。